The statement "Given its robust anti-inflammatory properties, Brilacidin offers patients a promising....." and the fact that Leo indicated if the B-OM trial was promising they would pursue the UP indication suggests that the B-OM trial is going well and we are simply waiting for the number of enrolled patients to meet threshold.

I would love to get a look at the interim results soon!